Holen Sie sich die Stockscreener-App
33.67
1.66%
-0.57
Vorhandelsmarkt:
33.68
0.010
+0.03%
Schlusskurs vom Vortag:
$34.24
Offen:
$34.365
24-Stunden-Volumen:
1.53M
Relative Volume:
1.33
Marktkapitalisierung:
$2.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-368.95M
KGV:
-6.0718
EPS:
-5.5453
Netto-Cashflow:
$-293.81M
1W Leistung:
+5.85%
1M Leistung:
-9.78%
6M Leistung:
-30.29%
1J Leistung:
+54.10%
1-Tages-Spanne:
$32.95
$34.70
1-Wochen-Bereich:
$30.97
$35.29
52-Wochen-Spanne:
$19.07
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
33.67 | 2.46B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics (VERA) Receives a Buy from Wells Fargo - The Globe and Mail
Vera Therapeutics moves closer to full approval for kidney disease drug after FDA alignment - MSN
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative - Yahoo Finance
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis - Yahoo Finance
(VERA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
Vera Therapeutics grants inducement awards to 10 new employees - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Grants Inducement Stock Awards to New Employees - Quiver Quantitative
Vera Therapeutics gives new hires 28,800 stock option shares - Stock Titan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Goldman Sachs Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Jefferies reiterates Vera Therapeutics stock rating on FDA alignment By Investing.com - Investing.com Canada
Vera Therapeutics stock gets Outperform rating from William Blair By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review - Investing.com UK
Why is Vera Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Vera Therapeutics Advances Atacicept for IgA Nephropathy with FDA Agreement - Intellectia AI
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path - Investing.com
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path By Investing.com - Investing.com Canada
Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops - Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment - Yahoo Finance
Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval - marketscreener.com
Goldman Sachs reiterates Vera Therapeutics stock rating on FDA timeline By Investing.com - Investing.com Canada
Vera Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
Why is Vera Therapeutics stock sliding today? - Investing.com
Raymond James reiterates Strong Buy on Vera Therapeutics stock By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review By Investing.com - Investing.com Australia
Vera Therapeutics stock rating reiterated at Buy by TD Cowen on FDA alignment - Investing.com Canada
Vera Therapeut aligns with FDA on earlier ORIGIN 3 eGFR analysis; eGFR readout in Q3 2026 - TradingView
Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA) - Stock Titan
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ... - Caledonian Record
FDA, Vera move up kidney trial analysis for potential new IgA nephropathy drug - Stock Titan
VERA News | VERA THERAPEUTICS INC (NASDAQ:VERA) - ChartMill
Vera Therapeutics, Inc. Files Form 8-K Detailing Company Information and SEC Compliance (May 21, 2026) - Minichart
Liquidity Mapping Around (VERA) Price Events - Stock Traders Daily
Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending (NASDAQ:VERA) - Seeking Alpha
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike - Stock Titan
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant - Stock Titan
Director at Vera Therapeutics (VERA) receives grant of 17,084 options - Stock Titan
Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading - Stock Titan
Vera Therapeutics (VERA) director awarded options on 17,084 shares - Stock Titan
Vera Therapeutics (VERA) awards director 17,084 stock options - Stock Titan
Director Patrick Enright awarded 17,084 Vera Therapeutics (VERA) stock options - Stock Titan
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $86 - Moomoo
BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):